Pre-made Atezolizumab benchmark antibody ( Whole mAb, anti-CD274/PD-L1 therapeutic antibody, Anti-B7-H/B7H1/PDCD1L1/PDCD1LG1 Antibody) for drug discovery and mechanism of action (MOA) research

Cat:GMP-Bios-ab-034
* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry
SKU GMP-Bios-ab-034 Category Tag

Product Details

Pre-Made Atezolizumab biosimilar, Whole mAb, Anti-CD274/PD-L1 Antibody: Anti-B7-H/B7H1/PDCD1L1/PDCD1LG1 therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.

Atezolizumab, sold under the brand name Tecentriq, is a monoclonal antibody medication used to treat urothelial carcinoma, non-small cell lung cancer (NSCLC), triple-negative breast cancer (TNBC), small cell lung cancer (SCLC), and hepatocellular carcinoma (HCC). It is a fully humanized, engineered monoclonal antibody of IgG1 isotype against the protein programmed cell death-ligand 1 (PD-L1).

Products Name (INN Index)

Pre-Made Atezolizumab biosimilar, Whole mAb, Anti-CD274/PD-L1 Antibody: Anti-B7-H/B7H1/PDCD1L1/PDCD1LG1 therapeutic antibody

INN Name

Atezolizumab

Target

CD274

Format

Whole mAb

Derivation

Humanized

Species Reactivity

Human

CH1 Isotype

IgG1

VD LC

Kappa

Highest_Clin_Trial (Jan '20)

Approved

Est. Status

Active

100% SI Structure

5x8l:FK:HM:GL:JO:SN

99% SI Structure

5xxy:HL

95-98% SI Structure

None

Year Proposed

2014

Companies

Amgen,ARCAGY/GINECO Group,BioLineRx,Chugai Pharmaceutical,Clovis Oncology,Dana-Farber Cancer Institute,Duke University,European Organisation for Research and Treatment of Cancer,Exelixis,Fondazione M

Conditions Approved

Non-small cell lung cancer,Urogenital cancer,Breast cancer,Small cell lung cancer

Conditions Active

Bladder cancer,Cervical cancer,Colorectal cancer,Fallopian tube cancer,Head and neck cancer,Liver cancer,Malignant melanoma,Ovarian cancer,Peritoneal cancer,Prostate cancer,Renal cell carcinoma,Anal

Conditions Discontinued

Hodgkin's disease,Myelodysplastic syndromes

Development Tech

Human Phage Display

Previous Name

NA

Gm Offical Target Name

CD274/PD-L1

Package

, ,

Genemeidi Omicron Variant Products
test
Previous
Next
This site uses cookies to offer you a better browsing experience. By browsing this website, you agree to our use of cookies.